New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of P...(tion by handlinga wide range of doses in...)

Date:8/27/2007

tion by handling a wide range of doses in less time to oncology pharmacists and nurses. The drug dosage is individualized to each patient on the basis of their body surface area. This is particularly important in administering Eloxatin(R) to the nearly 70 percent of patients with a body surface area of >1.76m2 who require at least 150 mg dosage of Eloxatin(R). In the past, pharmacists and nurses had to open two to four vials to prepare the necessary amount of Eloxatin(R) for these patients. However, with the introduction of the 200 mg vial, only one vial will be needed, not only saving time and effort, but also reducing the risk for mishandling, breakage and the volume of biohazardous waste disposal. With the same carton size as the 50 mg and 100 mg vials, the new 200 mg vial fits easily in pharmacy storage compartments without taking additional space.

"We will be using the new Eloxatin(R) 200 mg vial in our center in addition to the 50 mg and 100 mg vials because it offers increased efficiency and safety in preparing the most frequently needed doses," commented Timothy Tyler, PharmD, FCSHP, Director of Pharmacy Services Comprehensive Cancer Center, Desert Regional Medical Center, Palm Springs, CA. "Also, fewer vials reduce the number of hazardous device adaptors needed, resulting in added cost savings."

About Colorectal Cancer

Strides have been made in the management of colorectal cancer but it is still the second leading cause of cancer-related deaths in the United States. At stage II, the cancer has grown through the wall of the colon or rectum but has not yet spread to nearby lymph nodes. In stage III, the cancer has invaded one or more of the local lymph nodes but has not spread to distant sites. Metastatic (advanced) colorectal cancer means that the cancer has spread to other nodes and/or organs in the body. American Cancer Society estimates that in 2007 there will be about 112,340 new cases of colon cancer and 41,420 new cases of rectal canc
'/>"/>

SOURCE sanofi-aventis Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related biology technology :

1. Versatile Transfection Reagent Offers Low Toxicity and Consistent Performance
2. Ambion Offers Gene Expression Profiling Service
3. CIO Leadership Series: Snap-Ons Moreno offers lessons in IT transformation
4. Ethics Board site offers welcome contrast to state IT mistakes
5. Visions: Preizler offers insurers perspective on healthcare IT
6. Hewlett-Packard exec offers innovative counsel
7. Visions: Wade offers straight talk on e-medical records
8. Midwest offers non-stop flight to North Carolina research park
9. Failure of heart drug offers lessons for drug industry
10. MailFoundry offers new spam protection products
11. Sonic Foundry offers Mediasite to military families